Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price was down 0.2% during trading on Friday . The company traded as low as $8.76 and last traded at $8.81, with a volume of 66,515 shares. The stock had previously closed at $8.83.

A number of equities analysts have recently issued reports on OXFD shares. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Oxford Immunotec Global PLC in a research report on Monday, June 27th. Finally, Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday.

The stock has a 50-day moving average price of $9.00 and a 200 day moving average price of $10.07. The firm’s market cap is $198.81 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.32) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.32). During the same period in the previous year, the business posted ($0.31) EPS. The company had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $16.96 million. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. On average, analysts anticipate that Oxford Immunotec Global PLC will post ($1.25) EPS for the current year.

An institutional investor recently raised its position in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. increased its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned 4.74% of Oxford Immunotec Global PLC worth $12,293,000 as of its most recent filing with the SEC.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.